{"id":"abatacept-w12-w48","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-8","effect":"Hypertension"},{"rate":"2-4","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) works by interrupting the second signal required for full T-cell activation. It binds to CD80 and CD86 molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells. This selective costimulation blockade reduces pathogenic T-cell responses while preserving regulatory T-cell function, making it effective in autoimmune and inflammatory conditions.","oneSentence":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:29.601Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abatacept (W12-W48)","genericName":"Abatacept (W12-W48)","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}